Challenge to supplementary protection on Takeda ADHD drug falls flat in UK
September 25, 2026
| Melissa Ritti
A supplementary protection certificate which provided protection after patent expiry for the active ingredient in Takeda’s ADHD drug Elvanse in the UK was deemed valid there on Thursday. The ruling marks a blo... (more story)
Standard implementers warn of growing patent abuse: 'Consumer suffering is here'
September 25, 2026
| Nick Robertson
Costly infringement suits over standard-essential patents are reaching more industries and degrading the meaning of fair, reasonable and nondiscriminatory licensing negotiations, in a trend exacerbated by a ri... (more story)
Value Drug plausibly alleges Alkermes duped USPTO, judge says in antitrust suit
September 24, 2026
| Chris May
Value Drug has plausibly alleged global biopharmaceutical company Alkermes violated federal antitrust law by protecting its monopoly on the drug naltrexone through material misrepresentations to the US Patent ... (more story)
Collision appeal raises stakes for future of patent injunctions
September 24, 2026
| Nick Robertson
Opponents of restoring a presumption in favor of patent injunctions warned Wednesday that Collision Communications’ appeal against Samsung could reopen debate over the standard set by the US Supreme Court in e... (more story)
IP litigants can’t recover EUIPO legal costs through national courts, adviser says
September 24, 2026
| Inbar Preiss
IP litigants cannot use national court proceedings to recover legal costs beyond those available under EU Intellectual Property Office rules, an adviser to the EU’s top court said, while leaving broader questi... (more story)
This week at the UPC: Sept. 18-24
September 24, 2026
| Giorgi Dvalishvili and Inbar Preiss
The Unified Patent Court this week granted industrial tech giant Honeywell an injunction, while Samsung defeated Maxell after the patent at issue was revoked. Appeal judges also clarified costs during revocati... (more story)
IP licensing and business: Sept. 11-Sept. 24
September 24, 2026
| Steve Scherer
Licensing activity ranged across pharmaceuticals, cloud infrastructure, cybersecurity, connected vehicles, medical AI and data-center power, as companies struck drug-development and commercialization deals, tr... (more story)
China court factors token costs into damages for copied AI short drama
September 24, 2026
| MLex Staff
A Chinese court has factored token-related computing costs into damages for the unauthorized copying of an artificial intelligence-assisted short drama, while finding that the series qualified for copyright pr... (more story)